Deprecated: Assigning the return value of new by reference is deprecated in /fs2a/babybiotechs/public/wp-includes/cache.php on line 36

Deprecated: Assigning the return value of new by reference is deprecated in /fs2a/babybiotechs/public/wp-includes/query.php on line 15

Deprecated: Assigning the return value of new by reference is deprecated in /fs2a/babybiotechs/public/wp-includes/theme.php on line 505
NeurogesX to Buy or Not

NeurogesX to Buy or Not

This is the third and final part of Drew Waight’s guest series evaluating NeurogesX for investment. Thanks to Drew! If anyone else would like to do a guest series about a recent IPO, shoot me an e-mail (it’s in the about section).

NeurogesX financial details (2006):
Burn Rate: $30million
Liquid Assets: $14million
IPO price: $11.00
Raised in IPO:$44million

Fortunately in the case of NeurogesX we are looking at a company completing two secondary phase 3 trials so we don’t have to speculate too much about either the chances of their lead product, NGX-4010, being tolerated or effective. In addition this makes the financials a little easier to read as it’s relatively safe to assume that they will be able to get some revenue should the FDA fast track their NDA application expected to file in 2008.


As of December 31, 2006, NeurogesX has a deficit accumulated during the development stage of $127.5 million, and they further believe there is enough working capital to meet their obligations through the first half of 2007. Management plans to continue to finance the company’s operations with a combination of equity issuances, debt arrangements and revenues from collaborations with pharmaceutical companies, technology licenses and, in the longer term, product sales and royalties. In reference to the IPO, the S-1 states that Neurogesx plans to spend $40 million from the net proceeds to fund R&D. This roughly breaks down into $25 million to finish off NGX-4010 clinical and regulatory program for PHN and HIV-DSP, $10 million for NGX-4010 development for PDN program and the remaining $5 million for a new opioid analgesic product candidate. Looking at the above numbers it’s easy to guess that NGSX didn’t raise as much as expected during their initial public offering of 4 million shares. The shares were offered at $11 (after being reduced from $13) and closed down at $10.25 on the first day. Given the small amount of working capital, this indicates that even if NeurogesX continues to operate at their 2006 levels they won’t even have enough cash for two years. If this isn’t a problem it certainly is cutting it closer than I’m sure the management would have liked. Regardless, as was covered in the last post, NeurogesX plans to file their MAA with the EMEA this year, and, should this be successful, they would theoretically have the funds necessary to take NGX-4010 to the U.S. market at least for PHN and HIV-DSP.

NeurogesX Final Thoughts

NeurogesX stock price decreased nearly 30% in the first week of trading. Even though it is not atypical in biotech to see a drop in price the week following the IPO, it is possible to draw some logical conclusions as to why the stock has fallen. First of all, understanding the product NGX-4010, while actually straightforward, is a convoluted process in terms of gathering together previous studies and intellectual property. Combine this with the fact that there is no publicly available analysis of NeurogesX and very little “buzz” on the trade sites or blogosphere. The result of this marginally unexciting IPO is probably a cursory glance at the financials, which, to say the least, are less than optimal. Therefore from a financial standpoint investing in NeurogesX should give one some apprehension. However, from a market and science perspective this is a company holding the intellectual property license on a topical transdermal patch with high concentration of a natural compound for two underserved medical conditions. Because of this, even without two successful phase 3 trials, I would give NGX-4010 a much better chance of FDA approval than any small molecule or biologic. It is because NGX-4010 is so relatively close to being a product that I firmly believe that the ~$8 share price is substantially undervalued. That being said, I feel it would be less than prudent to bank on NGX-4010 being approved for PDN stateside, (however generously that would effect the market cap) due to the reasons explained previously. Personally I can’t think of a reason high concentration capsaicin should work some neuropathies and not others, but I’m in the business of investing my money and not gambling on unknowns. In summation, the largest risk involved with what I have just described as a bargain share price for a company with post-phase 3 treatments is going to come down to the financials. We all like a little wiggle room should things take longer than expected and I don’t feel that NeurogesX is leaving themselves that much. Conversely, I would be surprised that a company this close to the goal would ever be allowed fall short.


Since writing this article (Editor’s note: I was really slow getting it up) NeurogesX finished the second phase III trial of NGX-4010 for PHN and the stock surged to ~9$. Conversely during the first quarter ending in March they posted a wider loss totaling $11.4 million. Both of these events continue to support my synopsis of NGX-4010 being a promising therapeutic despite NeurogesX’ less than optimal financials.

30 Responses to “NeurogesX to Buy or Not”

  1. Chemnews is an online feed aggregator and retrieves syndicated web contents about chemistry science.
    This site is designed by Faranak Majidi , chemistry student of Tabriz university in Iran:

  2. Thanks for the great info. I hope you’ll follow this with some more great content.

  3. I am seaching for some idea to write in my blog… somehow come to your blog. best of luck. Eugene

  4. Nice post. Thank you for the info. Keep it up.

  5. Viagra on line….

    Viagra. Cheap viagra. Taking viagra with cialis….

  6. Thanks a lot for your assistance!

  7. I enjoy reading your post. Thank you very much for share nice information.

  8. I cant find your RSS feed i would like to subscribe to your content.

  9. а в каком это городе,какой стране??очень креативненько!!!!!)))))

  10. Hi that is a genuinely interesting view, It does give one food for thought, I am very delighted I stumbled on your blog, i was using Stumbleupon at the time, in any case i don’t want to ramble on too much, but i would like to say that I will be back when I have a little time to read your blog more thoroughly, Once again thanks a lot for the blog post and please do keep up the right work,

  11. Well, I’ve been following this blog with regard to right now and I would say I am beginning to like your post. :-D

  12. Skate Longboards

  13. hey, i really don\’t think in any doing this and you produce fine point.

  14. Your site article is extremely intersting and fanstic,simultaneously your blog style is unique and perfect,congrats.In order to business energy.

  15. I like this article a lot. I will certainly be back. Hope that I will be able to read more informative posts then. Will be sharing your wisdom with all of my friends!

  16. We have been checking out your posts and really love it. thanks for the great reads! do you ever do any bikecycling ?

  17. Well, well, well…what can we say about NGSX? Well, its monthly momentum is a short sellers dream. You had better think twice before bottom picking long this speeding train to hell stock. Until it breaks above 5.52 on a monthly close, I would not even consider buying it .

    The Momentum Report:


  18. This actually answered my personal downside, thank you!

  19. I invite you to check the new program for technical analysis.
    more information, visit:

    Please let me know, you can have a test Account.


  21. Cheers for this articles, It’s fantastic to see another blogEngine.NET user. Most folks these days seem to use other systems like WordPress, but I suppose blogEngine.NET is the best system to use.

  22. “/videos/” “Powered by zenphoto” “comment”

  23. I loved reading through this blog post.

  24. We must use time as a tool, not as a crutch.” John F. Kennedy

  25. Since MSI is touting this as a gaming laptop, it would naturally have an n - VIDIA Ge - Force graphic card. When it comes to basic, mainstream laptops, HP has the formula down.

  26. air jordan femme…

    The “Zhen” pass “in the” little master “who’s bedroom. But Zhen chaussure louboutin “living Shoukang palace,chaussure louboutin, an Ling living Yan air max tn Xi Gong,air max tn, Jing Fei and elegant move you really exist. The day before the e…

  27. As you upgrade you should be increasing the performance and overall value of your
    computer. Submitting to computer directories will attract more targeted users to your site compare with general directories.

    Our high end computers and mobile phones are results of electronic
    circuits and components.

  28. Celery contains about 5 calories, but it takes 10 calories to actually chew and digest therefore
    resulting in an overall deficit. Since this episode first aired, sales of raspberry ketones have skyrocketed, so much to the point that supplement companies can barely keep up with consumer demand.
    When reading reviews, never overlook or underestimate a reader comment.

  29. lunettes soleil ray ban…

    La cornée, les lentilles de contact comme un grand masque Wushang. Après taille ray ban l’hypoxie à long terme,taille ray ban, l’angiogenèse a augmenté à par ray ban pas cher femme tir du bord de la cornée au centre pour fournir de l’oxygèn…

  30. sacs louis vuitton…

    which would have earned two points for victory

    Gates,bottes louboutin, Bill: bottes louboutin Formerly hogan interactive outlet world’s richest man. But he’s not as rich as he would be had he not done business with Snyder. One of Six Flags’ big…

Leave a Reply